Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

Ähnliche Einträge

• Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects
  von: Zi‐yi Zhou, et al.
  Veröffentlicht: (2026)
• The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
  von: Chandrali S. Bhattacharya, et al.
  Veröffentlicht: (2024)
• Clinical study of the pharmacokinetics and pharmacodynamics of Xininurad tablets in patients with renal impairment
  von: Xiaoni Wang, et al.
  Veröffentlicht: (2025)
• Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects
  von: Kexu Yang, et al.
  Veröffentlicht: (2026)
• Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages
  von: Cheng‐jie Ke, et al.
  Veröffentlicht: (2025)